Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs.

Item

http://www.wikidata.org/entity/Q36563238

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs.

@ast

Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs.

@en

type

Item

label

Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs.

@ast

Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs.

@en

prefLabel

Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs.

@ast

Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs.

@en

P1476

Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs.

@en

P2093

Biqiang Zheng

http://www.w3.org/2001/XMLSchema#string

Chunmeng Wang

http://www.w3.org/2001/XMLSchema#string

Ruming Zhang

http://www.w3.org/2001/XMLSchema#string

Xi Cao

http://www.w3.org/2001/XMLSchema#string

Yingqiang Shi

http://www.w3.org/2001/XMLSchema#string

Yong Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.

Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

Biological and clinical review of stromal tumors in the gastrointestinal tract.

Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).

Surgery for gastrointestinal stromal tumour in the post-imatinib era.

P304

63-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3978/J.ISSN.1000-9604.2012.12.01

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23372343

http://www.w3.org/2001/XMLSchema#string

P932

3555300

http://www.w3.org/2001/XMLSchema#string